Lyra Therapeutics Inc (LYRA) — Cash Flow-to-Debt Ratio
Lyra Therapeutics Inc (LYRA) has a Cash Flow-to-Debt Ratio of -0.13x as of December 2025, meaning its operating cash flow of $-6.07 Million could theoretically repay 0% of its total liabilities ($46.83 Million) in one year. See LYRA cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Lyra Therapeutics Inc Cash Flow-to-Debt Ratio (2018–2025)
Historical debt coverage capacity for Lyra Therapeutics Inc across 8 annual periods. Also explore net asset growth rate of Lyra Therapeutics Inc to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Lyra Therapeutics Inc (2018–2025)
Year-by-year debt coverage analysis for Lyra Therapeutics Inc. For market capitalisation and broader financial context, see Lyra Therapeutics Inc (LYRA) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.62x | $-28.86 Million | $46.83 Million | ▲ +51.8% |
| 2024 | -1.28x | $-70.01 Million | $54.75 Million | ▼ -7.4% |
| 2023 | -1.19x | $-63.30 Million | $53.18 Million | ▲ +19.8% |
| 2022 | -1.49x | $-43.38 Million | $29.21 Million | ▼ -18.2% |
| 2021 | -1.26x | $-25.82 Million | $20.55 Million | ▲ +62.3% |
| 2020 | -3.34x | $-21.14 Million | $6.34 Million | ▼ -85.2% |
| 2019 | -1.80x | $-13.75 Million | $7.63 Million | ▼ -3492.9% |
| 2018 | -0.05x | $-6.64 Million | $132.43 Million | — |